292 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
15 Apr 13
Other Events
12:00am
Exhibit 99.1
GTx’s Phase III Clinical Studies of Enobosarm (GTx-024) To Continue as Planned Following Planned Safety Review
MEMPHIS, TN.— April 15 … , 2013—GTx, Inc. (Nasdaq: GTXI) today announced that a per protocol safety review of unblinded safety data on Friday April 12, 2013, by an independent
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
12 Jul 07
GTx’s Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
12:00am
Development of ACAPODENE on Course Following Planned Safety Review
MEMPHIS, Tenn., July 12, 2007, GTx, Inc. (Nasdaq: GTXI), today announced that a per … protocol interim safety review by an independent Data Safety Monitoring Board (DSMB) recommended that GTx continue clinical development as planned
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
5 Aug 14
GTx PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS
12:00am
, survival was assessed as a safety endpoint to determine that enobosarm treatment did not adversely affect survival. This quarter, a final analysis … ) and is evaluating the safety and efficacy of two doses (125 mg and 250 mg oral daily dosing) of GTx-758. The primary endpoint of the study is the proportion
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
7 Sep 06
GTx’s PHASE III CLINICAL DEVELOPMENT OF ACAPODENE ON COURSE FOLLOWING PLANNED SAFETY REVIEW
12:00am
DEVELOPMENT OF ACAPODENE ON COURSE FOLLOWING
PLANNED SAFETY REVIEW
MEMPHIS, TENN., September 5, 2006 — GTx, Inc. (Nasdaq: GTXI), the Men’s Health Biotech … Company, today announced that a per protocol interim safety review by an independent Drug Safety Monitoring Board (DSMB) recommended that GTx continue
8-K
ONCT
Oncternal Therapeutics Inc
14 Dec 06
Entry into a Material Definitive Agreement
12:00am
and conditions under which the design of the subject trial will be adequate for submission of the efficacy and human safety portion of a New Drug … extension trial for patients from the Phase III study to gather additional fracture and safety data. This Phase IIIb clinical study is a separate clinical
8-K
EX-99.1
bdlqf
29 Jan 14
Enrollment of the 125mg cohort is completed and 250mg cohort is currently enrolling
12:00am
8-K
EX-99.1
8e81qo
3 May 13
GTx PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS
12:00am
8-K
EX-99.1
anbvob9z 76uo
8 Dec 06
Termination of a Material Definitive Agreement
12:00am
8-K
EX-99.1
f8cy9u uhkgf
31 Jul 07
GTx, Inc. Reports Second Quarter 2007 Financial Results
12:00am
8-K
EX-99.1
62rh1osbowcxjpxm6 h0
27 Apr 06
Results of Operations and Financial Condition
12:00am
8-K
sk47vt 0ag5syg
15 Apr 13
Other Events
12:00am
8-K
EX-99.1
5k8tz zte2qi1uzh8b
8 May 12
GTx PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS
12:00am
8-K
EX-99.1
yz8abs
14 Sep 05
Other Events
12:00am
8-K
EX-99.1
yht ev7m14c65mz1g5
24 Apr 06
Other Events
12:00am
8-K
EX-99.1
5ccw8m65fo7h5nj
4 May 07
GTX, Inc. Reports First Quarter 2007 Financial Results
12:00am
8-K
EX-99.1
gt6k3p 6l1xcs
14 Mar 13
Enobosarm Phase 2 Trial for Muscle Wasting and Physical Function In Patients with Cancer Published In the Lancet Oncology
12:00am
8-K
EX-99.1
mlv8tn44vd azx
3 Oct 19
Regulation FD Disclosure
6:02am
8-K
EX-99.1
lssys3cp
6 Nov 08
GTX, Inc. Reports Third Quarter 2008 Financial Results
12:00am
8-K
EX-99.1
k8uol h5rpxayby
8 May 12
Other Events
12:00am
8-K
EX-99.1
1zjjnxuql92 jhszfue
22 Feb 07
GTxREPORTS FOURTH QUARTER AND YEAR END 2006 RESULTS
12:00am